Modern Healthcare Technology Holdings (0919) Fair Value & Analysis
Consumer Cyclical · HK · Market cap HK$80.5M
Fair value as of: Aug 13, 2026
From 14 valuation models · updated 2 days ago
Fair value updated Aug 13, 2026, revised from HK$0.2299 to HK$0.2179 (−5.2%) since Aug 5, 2026. Share price −4.9% over the past month.
A solid business, screening 183% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$0.2102). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
- The models converge in a tight band (HK$0.2102 to HK$0.2179), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0620 – HK$0.3600 · fair‑value band HK$0.2102 – HK$0.2179 · the HK$0.0770 price screens below the HK$0.2179 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Modern Healthcare Technology Holdings (0919) currently trades at HK$0.0770, while our model-based Fair Value estimate is HK$0.2179, implying the stock looks roughly 183.0% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Modern Healthcare Technology Holdings generated revenue of HK$454M at a net margin of 3.9%. Revenue declined 0.7% year over year. It earns a return on equity of 9.6%. The balance sheet holds a net cash position of HK$154M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.2102 (bear case) to HK$0.2179 (bull case); at HK$0.0770, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -14% fair-value upside, at 183%, 0919 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: DCF Models (HK$1.08) versus Asset-Based (HK$0.1400). Highest evidence: Growth DCF (80).
Notify me when 0919 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Modern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, Mainland China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products.
Full company description
Modern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, Mainland China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products. It offers beauty and facial services; aesthetics services, such as skincare treatment, professional consultation, skin care and anti-ageing, and referral services on plastic reconstruction; slimming services, including weight management programs; spa and massage services comprising resplendent bathroom furnishings and a hydrotherapeutic pool, as well as foot spa, and foot treatment and massage services; and haircare and removal, make-up, joint and intimate care, and body check and genetic test services. The company also sells skincare and wellness products under the be, FERRECARE, p.e.n, Y.U.E., Advanced Natural, Malu Wilz, Byotea, Care Plus, Mu-lan Spa, Cellnoc, Veribel, Castille, Dr Plus, IconX, Eclat du teint, and Natural Care brand names. In addition, it provides sub-franchising services in relation to beautification and gymnastic services; beauty and wellness treatment training program; property holding services; food and beverage services; fund management services; advertising services; maid agency services; licensing services; and management services, as well as holds property leases. The company was formerly known as Modern Beauty Salon Holdings Limited and changed its name to Modern Healthcare Technology Holdings Limited. The company was incorporated in 2005 and is headquartered in Kowloon Bay, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Modern Healthcare Technology Holdings reported revenue of HK$453M in FY2025 versus HK$431M in FY2021, a compound +1.2%/yr. Reported net income was −HK$5.1M in FY2025.
Watch 0919: get an alert when its fair value changes →
Peer Group
Personal Services · 43 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Personal Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Personal Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Rollins, Inc ROL | $36.52 | $21.11 | -42% |
| Service Corporation SCI | $84.40 | $38.27 | -55% |
| Frontdoor, Inc FTDR | $85.51 | $73.81 | -14% |
| H&R Block, Inc HRB | $54.18 | $78.30 | +45% |
| Bright Horizons Family Solutions Inc BFAM | $71.52 | $62.41 | -13% |
| Fu Shou Yuan International Group 1448 | HK$2.64 | HK$4.20 | +59% |
| Lungyen Life Service Corporation 5530 | 49.35 TWD | 31.33 TWD | -37% |
| Carriage Services, Inc CSV | $33.69 | $27.81 | -17% |
| Musti Group MUSTI | €15.05 | €14.08 | -6% |
| Uniao Pet Participacoes S.A AUAU3 | R$3.32 | R$1.20 | -64% |
Compare Modern Healthcare Technology Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Modern Healthcare Technology Holdings (0919) overvalued or undervalued?
What is the fair value of 0919?
What is the quality score of 0919?
What is the revenue of Modern Healthcare Technology Holdings (0919)?
What is the net profit margin of 0919?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Modern Healthcare Technology Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.